Methods for treating antipsychotic-induced weight gain

Patent metadata

Field	Value
Publication number	US-9517235-B2
Application number	US-201514813260-A
Country	US
Kind code	B2
Filing date	Jul 30, 2015
Priority date	Aug 23, 2010
Publication date	Dec 13, 2016
Grant date	Dec 13, 2016

Abstract

The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

First claim

What is claimed is:

1. A method of reducing diseases or disorders associated with the adverse metabolic profile of olanzapine by administering to a patient in need 10 thereof an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein said adverse metabolic effects comprise an increase in abdominal fat distribution, serum glucose levels, triglyceride levels or high density cholesterol.

3. The method of claim 1 , wherein said disease or disorder is diabetes.

4. The method of claim 1 , wherein said diseases or disorders are cardiovascular disorders.

5. The method of claim 1 , wherein the disease or disorder is obesity.

6. The method of claim 1 , wherein the disease or disorder is hypertension.

7. A method of lowering circulating ghrelin levels in a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:

or a pharmaceutically acceptable salt thereof.

8. A method of lowering circulating ghrelin levels in a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:

or a pharmaceutically acceptable salt thereof, wherein said ghrelin level is increased by the administration of an atypical antipsychotic.

9. The method according to claim 8 , wherein said atypical antipsychotic is olanzapine.

10. A method of lowering ghrelin levels in gastrointestinal tracts of a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:

or a pharmaceutically acceptable salt thereof.

11. A method of lowering ghrelin levels in gastrointestinal tracts of a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula:

or a pharmaceutically acceptable salt thereof, wherein said ghrelin level is increased by the administration of an atypical antipsychotic.

12. The method according to claim 11 , wherein said atypical antipsychotic is olanzapine.

Assignees

• Alkermes Pharma Ireland Ltd

Inventors

• Deaver Daniel
• Todtenkopf Mark

Classifications

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K31/554

  having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• C07D221/28

  Morphinans · CPC title

• A61K31/5513

  1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title